Regenxbio Q4 revenue rises but loss widens as costs increase

Regenxbio

05/03/2026 12:13

Overview

Biotech firm's Q4 revenue rose to $30.3 mln, driven by collaborations and royalties

Net loss for Q4 widened to $67.1 mln from $51.2 mln last year

Company advancing gene therapy pipeline with key milestones expected in 2026

Outlook

Regenxbio expects RGX-202 topline data in early Q2 2026

Company anticipates sura-vec wet AMD pivotal data in Q4 2026

Regenxbio forecasts cash to fund operations into early 2027

Result Drivers

COLLABORATIONS AND ROYALTIES - Revenue increase driven by collaborations and royalty monetization

RESEARCH AND DEVELOPMENT EXPENSES - Increased R&D expenses due to RGX-202 pivotal trials and manufacturing costs

PIPELINE ADVANCEMENT - Advancing gene therapy pipeline with key milestones expected in 2026

Company press release: ID:nPn7V2N5Va

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 License & Royalty Revenue
$27.15 mln
Q4 Net Income
-$67.15 mln
Q4 Operating Expenses
$87.97 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Regenxbio Inc is $29.00, about 217.3% above its March 4 closing price of $9.14

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)